Talon Compounding Pharmacy (Vita Pharmacy, LLC), San Antonio, TX

Is Talon Compounding Pharmacy (Vita Pharmacy, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Talon Compounding Pharmacy (Vita Pharmacy, LLC) hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The Colorado State Board of Pharmacy also lists nonresident license OSP 5883 for Vita Pharmacy, LLC dba Talon Compounding, San Antonio, TX, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018006 for TALON COMPOUNDING PHARMACY, SAN ANTONIO, TX, status CHANGE OF OWNERSHIP and license 054020992 for VITA PHARMACY LLC, SAN ANTONIO, TX, status NOT RENEWED, as of Nov 13, 2026.

Has Talon Compounding Pharmacy (Vita Pharmacy, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (May 13, 2026) and 1 FMD-145 letter (May 20, 2022) for Talon Compounding Pharmacy (Vita Pharmacy, LLC). Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city. The Colorado State Board of Pharmacy’s license dataset also lists 3 actions: “CLS Letter of Admonition” dated Oct 30, 2018, case 2018-4541 on nonresident license OSP 5883, “CLS Stipulation” dated Jun 18, 2014, case 2014-809 on nonresident license OSP 5883 and “CLS Stipulation” dated Dec 16, 2011, case 2012-945 on nonresident license OSP 5883.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Vita Pharmacy, LLC; Talon Compounding Pharmacy
Location
San Antonio, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
May 13, 2026
FDA Data Dashboard inspections
4 inspections: 3 OAI, 1 VAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 21 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Vita Pharmacy, LLC, (dba Talon Compounding Pharmacy), a 503A facility, with 3 dated actions.

Document
May 13, 2026Warning letter close-outWarning Letter Close Out Issued 05/13/2026fda.gov
May 20, 2022FMD-145 letterFMD-145 Letter Issued 05/20/2022Not linked by FDA
Oct 6, 2021Form 483483 Issued 10/06/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Vita Pharmacy, LLC, San Antonio, TX (FEI number 3009192575), matched to this page by exact name, city and state. It lists 4 inspections: 3 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 6, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30091925751153854
Aug 3, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30091925751061914
Jun 29, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009192575976566
Jun 24, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3009192575930632

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 21 numbered observations in all, across 3 inspections ending Jun 24, 2015 to Oct 6, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 23, 2021 to Oct 6, 2021: 3 observations

Firm on the cover
Vita Pharmacy, LLC dba Talon Compounding Pharmacy, 2950 Thousand Oaks Dr Ste 25, San Antonio, TX 78247-3347
FEI number
3009192575
Establishment type on the cover
Sterile and Non-sterile Drug Producer
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The facility design was observed to allow the influx of poor quality air into a higher classified area.

Specifically,

A. Your cleanroom design includes the ISO 5 classified area air exhausts, which vents along the floor into a non-classified/ non differential pressure monitored/controlled area containing dusk particulates on the floor. Your pharmacy has identified this area as an ISO Class 8. Your pharmacy uses this area for storage along with <Redacted B4> and <Redacted B4> processing area for <Redacted B4> and sterilization of aseptic processing utensils and components. The area also has an unrestricted doorway entering your pharmacy's non-sterile hazardous drug processing area. Your firm's cleanroom design failed to prevent contamination and lower quality air from entering your ISO 5 sterile drug compounding area from the non-classified area identified as an ISO Class 8 which is assessed <Redacted B4>. There have been no changes made in the cleanroom overall design since the previous FDA inspection. This is a repeat observation.

B . ...

Read the full 483 (PDF on fda.gov)

Observation 2

IS0-5 classified areas were not certified under dynamic conditions.

Specifically, during your pharmacy's cleanroom re-certification, unidirectional airflow was not verified under operational (dynamic) conditions where all equipment (mixers and~<Redacted B4> used during aseptic processing in addition to pharmacy technician simulating drug product processing was in use and being performed within the ISO S processing area. Your firm's clean room re-certification reports tests dated 8/25/2021, 10/23/2020, 8/19/2020, 8/9/2019 and 4/10/2019 were documented as being performed in dynamic conditions. No aseptic simulations and equipment were in use and performed at the time of the documented cleanroom. This Is a repeat observation.

Observation 3

Your firm handled hazardous drug products without adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.

Specifically, during a walkthrough of your pharmacy's non-sterile hazardous drug processing area, your pharmacy was observed using an air blower, underneath the table, to dry utensils. At the same time, your pharmacy technician was in the middle of processing a batch of non-sterile hazardous drug product, ANAS0.07MG/B12-1MG/ B7-10MG/COQ10-100MG/ FINAS2.SMG RESV 200MG/TADALSMG/ VITD3-40001U/ ZN 30MG K-CAPS #509 Capsules, Lot# 09172021:48, BUD 2/28/2022. Your pharmacy PIC reported no laboratory testing is performed on any processed non-sterile drug products.

pharmacy technician was in the middle of processing a batch of non-sterile hazardous drug product, ANAS0.07MG/B12-1MG/ B7-10MG/COQ10-100MG/ FINAS2.SMG RESV 200MG/TADALSMG/ VITD3-40001U/ ZN 30MG K-CAPS #509 Capsules, Lot# 09172021:48, BUD 2/28/2022. Your pharmacy PIC reported no laboratory

testing is performed on any processed non-sterile drug products.

Inspection Jul 26, 2018 to Aug 3, 2018: 8 observations

Firm on the cover
, 2950 Thousand Oaks Dr Ste 25 Talon Compounding Pharmacy, San Antonio, TX 78247- 3347
FEI number
3009192575
Establishment type on the cover
Compounding Pharmacy
FDA district office on the cover
DISTRICT ADDRESS AN D PHONE NUMBER 4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Your facility design allowed the influx of poor quality air into a higher classified area.

Observation 2

Personnel engaged in aseptic processing were observed with exposed hair.

Specifically, on 7/26/2018 while observing your firm's pharmacy technician aseptically compounding 2 lots of sterile Tri-Mix Injection (Lot 07252018:91, BUD 1/21/2019; and Lot 07262018:52, BUD 1/22/2019), I observed your pharmacy technician hair sticking out from underneath the hairnet. On more than eight occurrences, your pharmacy technician entire head extended into your ISO 5 area while aseptically processing both sterile drug lots.

Observation 3

Personnel did not disinfect to prevent contamination.

Specifically, your firm's pharmacy technician failed to disinfect gloves to prevent contamination. For example, while conducting visual observations on 7/26/2018, 7/31/2018, and 8/1/2018, I observed your firm's pharmacy technician while aseptically manipulating a sterile finished drug product leave the ISO 5 classified area to select additional processing components within the ISO 7 classified area and return without re-disinfecting sterile gloves prior to reentering the aseptic processing area on too many to count occasions.

Observation 4

Equipment was not disinfected prior to entering the aseptic processing areas.

Specifically, equipment and materials and/or supplies were not disinfected prior to placing these items into to the ISO 5 aseptic processing area. For example, while conducting visual observations on 7/26/2018, 7/31/2018, and 8/1/2018, I observed your firm's pharmacy technician placing drug components into the cleanroom <Redacted B4> without disinfecting with sterile <Redacted B4>. Drug components were then transferred from your firm's ISO 7 to the ISO 5 aseptic processing area without disinfecting with sterile <Redacted B4> and used to aseptically process sterile patient-specific drug products.

Observation 5

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worse-case activities and conditions that provide a challenge to aseptic operations.

Specifically, your firm's media fill simulation fails to represent the worst-case scenario and simulate actual production conditions. For example, You firm's media fill simulation consists of aseptically <Redacted B4>. Your firm PIC reported the potential maximum number of vials aseptically processed can be <Redacted B4> for a specific sterile drug lot. Your firm's aseptic processing does not include the filling of IV bags. Instead, your firm aseptic processing includes vial and syringe filling only for sterile drug compounding.

Observation 6

There is a lack of adequate controls to prevent mix-ups.

Specifically, Incident Report dated 10/10/2017, reported Rx <Redacted B4>, Lot# 08292017:77 was incorrectly labeled as Testosterone 4% Topical CRM and was dispensed. The correct label should have been Testosterone 4mg/mL Topical CRM. Your firm failed to detect the labeling enor for approximately 1 year, until your technician was typing a new prescription for the patient.

Observation 7

Cleanroom certification for your ISO classified areas are inadequate.

Specifically, your firm's cleanroom certifications are documented as being performed in the dynamic (operational) condition. Your firm failed to include the use of the <Redacted B4> Ias part of your firm's ISO 5 cleanroom smoke study and certification.

Observation 8

There is a lack of adequate separation within facility design and equipment placement within the ISO classified and non-classified areas to prevent contamination.

Specifically,

A. Your cleanroom is designed with plastic flaps along the floor which function as air exhausts for the ISO 5 classified area which vents into the ISO 8. Your firm's cleanroom design failed to prevent contamination of your ISO 5 sterile drug compounding area. This is a repeat observation.

This is a repeat observation.

B. Your firm has a refiigerator/freezer within your firm's ISO 5 classified area used as part of your firm's <Redacted B4> process. Your firm failed to prevent contamination from the refiigerator/freezer and transferred into the ISO 5 sterile compounding area.

C. Your firm placement of the <Redacted B4> is located within your ISO 8 classified area. The <Redacted B4> location is on the opposite side of the wall where your firm has designated as ISO 5. There is a plastic flap along the floor which separate both areas and remains open. Your firm failed prevent the introduction of contamination from the <Redacted B4> from entering your ISO 5 classified area.

Inspection Jun 15, 2015 to Jun 24, 2015: 10 observations

Firm on the cover
, 2950 Thousand Oaks Dr Ste 25 Talon Compounding Pharmacy, San Antonio, TX 78247-3347 Producer of Sterile Drug Products
FEI number
3009192575
FDA district office on the cover
4040 North Centr al Expressway, Sui te 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

A) During the course of our inspection at your firm, we observed the IS0-5 designated cleanroom has been constructed of REDACTED B4 openings approximately REDACTED B4 off the floor, and spaced approximately REDACTED B4 apart all around the perimeter of the room. These openings are covered by transparent plastic flap coverings. This design renders the plastic flaps as the sole barrier between the IS0-5 cleanroom and the unclassified room. During our inspection, we observed that these flaps had continuous air flow coming out of them from the IS0-5 cleanroom into the unclassified room, causing an open space between the IS0-5 cleanroom and the unclassified area.

B) You have no smoke studies to verify the direction of the air flow in your IS0-5 cleanroom.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

Specifically,

Your firm's SOP entitled, "Cleaning and Disinfection", Revised 3/14/14, specifies that "All cleaning activities should take place REDACTED B4 however,

A) On 06/15/2015, during the preparation of BI-MIX PAPA VERINE 30/PHENTOLAMINE 2 INJ INJECTABLE, Lot

#06122015:23, Best Used By: 12/09/2015, we observed an operator in the ISO 5 cleanroom using Sterile - REDACTED B4

REDACTED B4 to spray the countertops during API dissolution into solution while a REDACTED B4 containing the preparation of BI-MIX PAPA VERINE 30/PHENTOLAMINE 2 INJ INJECTABLE, Lot #06122015:23, Best Used By: 12/0912015Bl-]I.{[X was left uncovered and exposed.

B) On 06/16/2015, at approximately 2:05 pm, during the preparation of Testosterone Cypionate 200MGIML in oil Injectable (lot 06162015:39), we observed an operator in the ISO 5 cleanroom using REDACTED B4 for facility cleaning during API dissolution into solution. During this cleaning period, six amber vials were found exposed on the counter-top without lids. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm prepares "non-sterile to sterile products" which your firm's owner designated as "High risk

compounding category", but, does not have any written procedure for evaluating the "Beyond use date" for the preparations. The products such as Triamcinolone diacetatc 40mg/ml (10 ml vial) and Papaverine-30mglmVPhentolamine -lmg/mi/Prostaglandin -lOmcg/ml Injection were found to have "Beyond use date" as five months and six months, respectively, but data to support the BUD was not available. Specifically, sterility tests and endotoxin tests were not performed to support the BUD.

Observation 4

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically,

On 06/15/2015, while an operator was gowning in the anteroom, we observed that the sleeve of the operator made contact with the floor of the anteroom. Following contact of the garb with the floor, no corrective action was initiated. This operator then entered the IS0-5 cleanroom. Subsequently, we asked the firm for information regarding the gowning garb. The firm provided us with boxes of indicated garb. These items, listed below, are non-sterile:

- White Bouffant Caps manufactured by Pro Advantage by NDC (REF P70 1 020); -Procedure Mask manufactured by 3M (REF 1820); -Gown manufactured by Medline (Item NONCV700L); -Basic Shoe Covers, Universal, Nonconductive manufactured by CardinaiHealth (REF 2850)

A dditionally, when in the IS0-5 cleanroom, the operator had exposed skin surfaces on REDACTED B4 neck and face area. Furthermore, we did not observe any cleanroom personnel wearing protective eyewear at any time during the inspection. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other drug products that may have been associated with the specific failure or discrepancy.

Specifically,

The product "T3 13.5 mcg I T4 57 meg Capsule, lot# 112520 14:34" was tested for potency REDACTED B4. The REDACTED B4 results were reported as 76.1% for ingredient T3 and 80.2% for ingredient T4 and indicated as "Variation of active within formulation observed"; however, at REDACTED B4 the results were reported as 90.9% for ingredient T3 and 92.3% for ingredient T4. Furthermore, the laboratory results as "Meets USP potency requirements". Your Pharmacist in Charge indicated that this variability in potency test results are routinely observed and may be due to inconsistent mixing. Your firm's owner indicated that the root cause of the inconsistency has not been determined, but continues utilizing similar methods despite the variability.

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

Specifically,

A) Your firm utilizes REDACTED B4 to sterilize amber vials and rubber stoppers used to store sterile injectables. On 06/17/2015, we requested your validation for the repeatability and reproducibility of the REDACTED B4 provided us with REDACTED B4 MANUAL". A

number of sections were highlighted, including suggested REDACTED B4. We further inquired about your validation and method for ensuring appropriate functionality of this instrument. You indicated that there was not such documentation. You stated that you use REDACTED B4 to ensure sterility. B) Your firm utilizes a REDACTED B4 for the production of injectables. Your firm did not perform any equipment qualification prior to use to determine the adequacy of the equipment. Additionally, your firm did not perform validation activities to determine REDACTED B4 for the procedure followed. ...

Read the full 483 (PDF on fda.gov)

Observation 7

There was a failure to handle and store components at all times in a manner to prevent contamination.

Specifically,

On 06/15/2015, we observed the following components to be out of the expiration dates:

REDACTED B4 Expiration Date: 03/31/2015. REDACTED B4 . Best Used By 04/30/2015 . REDACTED B4, Expiration Date: 03/31/20 15. REDACTED B4 Best Used By: 5/31/2015 REDACTED B4

Observation 8

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically,

On 06/15/2015, we observed the preparation of BI-MlX PAPAVERINE 30/PHENTOLAMJNE 2 INJ injectable solution, Lot #061220 15:23, Best Used By: 12/09/2015, in the IS0-5 room. During operations in this cleanroom environment, we observed a large number of scattered papers on a table adjacent to the facility's REDACTED B4. Additionally, on the lower shelf of this referenced table, a number of glass and plastic bulk containers were observed.

Observation 9

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Your firm's Facility Maintenance SOP entitled, "Cleanroom Monitoring and Certification", Revised 05/06/14, specifies that "the environment in the cleanroom will be monitored REDACTED B4 and the REDACTED B4 should be REDACTED B4 in REDACTED B4 locations in tbe cleanroom. Your Pharmacist in Charge also indicated that the REDACTED B4 are REDACTED B4 locations as identified on the environmental monitoring records. However, your firm does not have records substantiating REDACTED B4 testing. The previous three tests were conducted on REDACTED B4 and REDACTED B4. Additionally, records were reviewed dating back until June of 2013 and the following inconsistencies were observed in the environmental monitoring documentation: -12/18/14 -Records indicate only REDACTED B4 were used and only REDACTED B4 of monitoring. -12/11/14-Records indicate only REDACTED B4 were used and only REDACTED B4 of monitoring. -10/13/14-Only REDACTED B4 were indicated.

Observation 10

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.

Specifically,

A) You do not have any endotoxin testing performed, and only perform sterility testing on REDACTED B4

' B) You do not perfo rm REDACTED B4

C) There is no validation of your sterilization methods.

DA TES OFlNSPECTION: 06 /l5/2015 (Mon), 06/l6/2015 (Tue), 06/l7/2015 (Wed), 06/18/2015 (Thu), 06/24/2015 (Wed)

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5883OSPVita Pharmacy, LLC dba Talon CompoundingSan Antonio, TXExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018006LICENSED PHARMACYTALON COMPOUNDING PHARMACYSAN ANTONIO, TXCHANGE OF OWNERSHIP
054020992LICENSED PHARMACYVITA PHARMACY LLCSAN ANTONIO, TXNOT RENEWED

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.